Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting
This real-world analysis suggests that ibrutinib may be safely used in the majority of CLL patients encountered in routine practice.
Authors
- Samaneh Bayati
- Eric Sy (ORCID: https://orcid.org/0000-0001-5033-797X)
- Karolina Grzyb
- Kayla Cropper
- Y. S. Chang
- Sandy Kassir (ORCID: https://orcid.org/0000-0003-2125-6390)
- Waleed Sabry (ORCID: https://orcid.org/0000-0001-8912-5771)
- Shubrandu Sanjoy (ORCID: https://orcid.org/0000-0003-4773-6368)
- Seyedeh Zahra Moossavi
- Ibraheem Othman (ORCID: https://orcid.org/0000-0001-5673-9945)
Institutions
- Saskatchewan Health Authority (CA)
- Saskatchewan Health (CA)
- University of Saskatchewan (CA)
- Saskatchewan Cancer Agency (CA)
- Saskatoon Medical Imaging (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-05-23
- DOI
- https://doi.org/10.3390/curroncol32060296
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63
Funders
- Janssen Biotech